Metavia Inc. · NASDAQ:MTVA
Metavia — NeuroBo Pharmaceuticals — Investor Presentation (February 2024)
26 slides from Metavia's investor presentation, Feb 14, 2024
Slide 1: NeuroBo Pharmaceuticals, Inc.
December 2023 NASDAQ: NRBO 1 February 2024 NeuroBo Pharmaceuticals, Inc.
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the us
Slide 3: Strong Leadership Team
3 Strong Leadership Team Management Team Hyung Heon Kim, Chief Executive Officer Robert Homolka, SVP Clinical Operations Stephen Harrison, M.D., Consulting Chief Medical Officer Sung-Jin Kim, Pharmacist, Director of Corporate Strategy Mi-Kyung Kim, Ph.D., RPh, Chief Scientific Officer Marshall H. Wo
Slide 4: Compelling Investment Opportunity Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics
4 Compelling Investment Opportunity Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics ▪ Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1241 ✓ Open IND for Treatment of MASH and Type 2 Diabetes ✓ Actively recruiting into a Pha
Slide 5: Pipeline
5 Pipeline Asset Preclinical Phase 1 Phase 2 DA-1241 (GPR119 Agonist) DA-1726 (GLP1R/GCGR Dual Agonist) 2a 2b OBESITY Indication Phase 3 MASH Obesity
Slide 6: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
6 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and planned DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success H1 2025 Meeting with FDA 2024 2025 H2 2025 Phase 2b Protocol Sub
Slide 7: DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
December 2023 NASDAQ: NRBO 7 DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
Slide 8: DA-1241: Competitive Differentiation
8 DA-1241: Competitive Differentiation 1. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3 Resmetirom DA-1241 Developer Madrigal NeuroBo Indication MASH MASH Status Phase 3 completed NDA Submitted Phase 2 Action THR (Thyroid
Slide 9: DA-1241 Effect on Pathogenesis in MASH as a Monotherapy
9 DA-1241 Effect on Pathogenesis in MASH as a Monotherapy GPR119 activation: Monocytes and macrophages ▪ Macrophage activation ▪ Monocyte recruitment ▪ Macrophage differentiation → Reduction in hepatic and systemic inflammation Hepatic stellate cells Stellate cell activation → Reduce hepatic fibroge
Slide 10: GPR119 in Glucose Control when Co-Administered with Other Therapies
10 GPR119 in Glucose Control when Co-Administered with Other Therapies ▪ Effectively decreased hepatic inflammation ▪ Reduced systemic inflammation and fibrosis biomarkers ▪ Reduced hepatic lipid and collagen deposition in the liver of MASH mice Activation of GLP1 Receptor Effects ▪ Pancreas • Incre
Slide 11: DA-1241: Differentiated Anti-Inflammatory Effect in MASH Mice
11 DA-1241: Differentiated Anti-Inflammatory Effect in MASH Mice (1-3) ▪ DA-1241 was shown to improve BOTH hepatic and systemic inflammation effectively ▪ Co-administered with a DDD4 potentiated the anti-inflammatory effect 38 100 84 68 58 103 0 20 40 60 80 100 120 Change in Plasma Inflammatory Cyto
Slide 12: Combo: Synergistic Effects with a DPP4 Inhibitor in DIO-MASH Mice
12 Combo: Synergistic Effects with a DPP4 Inhibitor in DIO-MSH Mice ▪ Increased plasma active GLP-1 in DIO-MASH mice ▪ Augmented improvement in steatosis, inflammation, and fibrosis compared to monotherapy ▪ Inhibited stellate cell activation (αSMA+ area) further in the liver ▪ Improved Fibrosis-rel
Slide 13: DA-1241: Ongoing Phase 2a in MASH
13 DA-1241: Ongoing Phase 2a in MASH Support use as a monotherapy Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis Primar
Slide 14: DA-1241: Potential Advantages in MASH
14 DA-1241: Potential Advantages in MASH DA-1241 Potential Advantages in MASH ▪ GPR119 therapeutic target is to inhibit steatosis, inflammation and fibrosis and the treatment or progression of MASH ▪ DA-1241 is an advanced GPR119 agonist with proven enhanced efficacy in animal models ▪ Its effect is
Slide 15: DA-1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
December 2023 NASDAQ: NRBO 15 DA -1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
Slide 16: DA-1726: Competitive Differentiation
16 DA-1726: Competitive Differentiation Survodutide Mazdutide DA-1726 Semaglutide Tirzepatide Developer Boehringer Ingelheim Innovent Biologics Lilly NeuroBo Novo Nordisk Lilly Indication Obesity Obesity Obesity Obesity Obesity Status Phase 2 completed Phase 3 (China) Phase 1 (USA) Phase 1 Initiatio
Slide 17: DA-1726: Mechanism of Action
17 DA-1726: Mechanism of Action DA-1726 is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/Glucagon Receptor); GLP-1 (Glucagon-Like Peptide 1) 1. Pocai A. Mol Metab.2014;3:241-51 ▪ Oxyntomodulin
Slide 18: DA-1726: Therapeutic Potential in Obesity — Semaglutide Comparison
18 DA-1726: Therapeutic Potential in Obesity(1-3) — Semaglutide Comparison DA-1726 outperformed Semaglutide (WEGOVY ), a GLP-1 agonist, in mouse models of obesity* *Statistically significant compared to control Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); HF-DIO (High Fat
Slide 19: DA-1726: Therapeutic Potential in Obesity — Tirzepatide Comparison
19 DA-1726: Therapeutic Potential in Obesity (1,2) — Tirzepatide Comparison DA-1726 shows similar weight loss while consuming more food compared to Tirzepatide (Mounjaro ) Notes: HF-DIO (High Fat-Diet Induced Obesity); BWL (Body Weight Loss) 1. Dong-A Study Report 105497. All treatments given as twi
Slide 20: DA-1726: Phase 1 Study to Evaluate PK/PD and Safety
20 DA-1726: Phase 1 Study to Evaluate PK/PD and Safety Rationale for study ▪ Gain a robust understanding of safety, tolerability of various dose levels in humans. ▪ Superior weight loss compared with the pair-fed group, indicating much of the weight loss was attributed to reduced food intake via act
Slide 21: Financials and Capitalization
December 2023 NASDAQ: NRBO 21 Financials and Capitalization
Slide 22: Cash Balance and Capitalization Table
22 Cash Balance and Capitalization Table Cash Balance As of September 30, 2023 Cash $25.8 million Debt none Capitalization Table as of December 31, 2023 Common Stock Equivalents Common Stock 4,906,032 Warrants (WAEP $145.54)(1) 203,914 Options (WAEP $398.30) 4,700 Common Stock Shares Available for I
Slide 23: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
23 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and planned DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success H1 2025 Meeting with FDA 2024 2025 H2 2025 Phase 2b Protocol Su
Slide 24: Investment Thesis
December 2023 NASDAQ: NRBO 24 Investment Thesis
Slide 25: Compelling Investment Opportunity Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics
25 Compelling Investment Opportunity Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics ▪ Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1241 ✓ Open IND for Treatment of MASH and Type 2 Diabetes ✓ Actively recruiting into a Ph
Slide 26: Thank You!
December 2023 NASDAQ: NRBO 26 Thank You! Investor Contacts: Rx Communications Group Michael Miller +1 917.633.6086 mmiller@rxir.com NeuroBo Pharmaceuticals Marshall Woodworth +1 919.749.8748 marshall.woodworth@neurobopharma.com
NeuroBo Pharmaceuticals — Investor Presentation (February 2024) on 6ix